Incyte stock price target maintained at $152 by H.C. Wainwright on cancer drug data

Phase 1 results for Incyte’s INCB161734 combined with chemotherapy showed overall response rates of 69% (18 of 26 patients) with gemcitabine/nab-paclitaxel and 89% (24 of 27) with modified FOLFIRINOX; six-month progression-free survival was 80% and 90%, respectively. H.C. Wainwright reiterated its Buy rating and $152 target, while noting DAWN-303 could provide a mid-2027 response-rate analysis; the reported response rates include unconfirmed responses. Other analysts expressed mixed views, with targets ranging from $119 to $127 and ratings from Neutral to Outperform, while Jakafi is expected to lose exclusivity in December 2028.

Analysis

The investable signal is clinical optionality, not proof of a differentiated product: small Phase 1 cohorts, unconfirmed responses, short follow-up and chemotherapy combinations leave durability, tolerability and the drug’s incremental contribution unresolved. The two regimens should not be ranked against each other; they are different cohorts and backbones. The randomized DAWN-303 comparison is the key de-risking step. Until it shows a clear benefit over chemotherapy, the response rates support a hypothesis rather than a reliable revenue forecast.

In the near term, the headline may lift INCY on pipeline enthusiasm, but an analyst target is not validation and may amplify expectations ahead of controlled data. Over 1–3 months, look for safety, dose selection, confirmation of responses and enrollment details; absent those, excitement can fade. Over 6–18 months, trial maturation may sharpen the asset’s value, while the much nearer strategic question is whether the broader pipeline can replace Jakafi economics ahead of its expected 2028 exclusivity loss. A successful KRAS G12D program could improve Incyte’s negotiating position and diversify its portfolio, but competing development by Revolution Medicines and others raises the bar for clinical differentiation.

Contrarian view: investors may be over-weighting response rates and under-weighting the randomized evidence, development time and eventual commercial competition. Conversely, discounting the program entirely would miss meaningful upside if a controlled trial confirms durable incremental benefit.

Key Decisions for Investors

• Do not chase the headline as a standalone catalyst. For existing INCY exposure, treat INCB161734 as pipeline optionality, not yet as an offset to Jakafi’s eventual loss of exclusivity.
• Set an alert for DAWN-303 design, enrollment, safety and response-confirmation updates. Upgrade conviction only if randomized data demonstrate incremental and durable efficacy versus the chemotherapy control; worsening tolerability or failure to confirm responses falsifies the bullish clinical thesis.
• For a new position, prefer staged entry after the initial reaction or wait for stronger trial evidence rather than anchoring to analyst price targets. The main near-term risk is reversal of sentiment before a controlled readout; the more material upside catalyst is evidence that the drug adds benefit beyond chemotherapy.
• Track competing KRAS G12D programs, particularly Revolution Medicines, alongside Incyte’s data: faster or more durable competitor results could compress the commercial opportunity even if INCB161734 remains active.